<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13414">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932293</url>
  </required_header>
  <id_info>
    <org_study_id>H&amp;H_SODAPI II</org_study_id>
    <nct_id>NCT02932293</nct_id>
  </id_info>
  <brief_title>Triple Combination DAAs for Treating HCV GT1b Subjects</brief_title>
  <official_title>Triple Combination DAAs for Ultra Short Duration Therapy for HCV Genotype 1b in Chinese (SODAPI II Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanity &amp; Healthy GI and Liver Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanity &amp; Healthy GI and Liver Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is only one kind of treatment (simeprevir 150 mg + sofosbuvir 400 mg+daclatasvir 60
      mg) in this study but the treatment duration may be different depending on patients'
      response to the antiviral therapy and whether patients have liver cirrhosis. If patients
      have no cirrhosis and the HCV viral load on day 2 is &lt;500 IU/ml, patients will receive
      sofosbuvir, daclatasvir and simeprevir for 3 weeks, otherwise the treatment duration is 4
      weeks. If patients have cirrhosis and the HCV viral load on day 2 is &lt;500 IU/ml, patients
      will receive sofosbuvir, daclatasvir and simeprevir for 6 weeks, otherwise the treatment
      duration will be 8 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with plasma HCV viral load below the lower limit of quantification for 12 weeks after treatment completion (SVR12)</measure>
    <time_frame>Post treatment Week 12</time_frame>
    <description>SVR12 is defined as HCV RNA &lt; lower limit of quantification (LLOQ) 12 weeks after last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of circulating HCV RNA during treatment and after treatment discontinuation</measure>
    <time_frame>Baseline up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with on-treatment virologic breakthrough and relapse</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Viral breakthrough is defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) during treatment, but did not achieve a sustained virologic response (SVR). Viral relapse is defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) within 4 weeks of end of treatment, but did not achieve an SVR up to 24 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>SOF+DCV+SMV 3-4 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is &lt;500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is &gt;500 IU/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+DCV+SMV 6-8 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is &lt;500 IU/ml or (b) 8 weeks if HCV VL on day 2 is &gt;500 IU/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF+DCV+SMV</intervention_name>
    <description>Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.</description>
    <arm_group_label>SOF+DCV+SMV 3-4 wks</arm_group_label>
    <arm_group_label>SOF+DCV+SMV 6-8 wks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HCV RNA positive &gt;2000 IU/ml or NAT POC positive

          2. Genotype 1b

          3. CP score ≤6

        Exclusion Criteria:

          1. Pregnant or nursing female or male with pregnant female partner

          2. Hematologic or biochemical parameters at Screening outside the protocol- specified
             requirements

          3. Active or recent history (≤ 1 year) of drug or alcohol abuse

          4. Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin
             cancers)

          5. History or current evidence of any condition, therapy, laboratory abnormality or
             other circumstance that might confound the results of the study, or interfere with
             the subject's participation for the full duration of the study, such that it is not
             in the best interest of the subject to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George LAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanity &amp; Health Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yudong WANG, PhD</last_name>
    <phone>+85228613777</phone>
    <email>danny.wang@hnhmgl.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 12, 2016</lastchanged_date>
  <firstreceived_date>October 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simeprevir</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
